Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study - PubMed (original) (raw)
Clinical Trial
Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study
C P Morrow et al. Gynecol Oncol. 1991 Jan.
Abstract
Between June 20, 1977 and February 5, 1983, the Gynecologic Oncology Group entered 1180 women with clinical stage I or II (occult) endometrial carcinoma into a surgical-pathological staging study. Eight hundred ninety-five patients with endometrioid or adenosquamous carcinoma were evaluable for this study which relates surgical-pathological parameters and postoperative treatment to recurrence-free interval and recurrence site. Proportional hazards modeling of time to recurrence was performed. For patients without metastasis determined by surgical-pathological staging the greatest determinant of recurrence was grade 3 histology adenocarcinoma grade 3, relative risk (RR) = 15; adenosquamous carcinoma grade 3, RR = 8.1; all adenocanthomas, RR = 1.0). Of 48 patients with histologically documented aortic node metastases, 47 had one or more of the following features: (1) grossly positive pelvic nodes, (2) grossly positive adnexal metastasis, or (3) outer one-third myometrial invasion. Pelvic radiation was administered to 48.0% and vaginal brachytherapy alone to 10.2% of patients postoperatively; 41.8% received no adjuvant radiation therapy. None of three recurrences in the vaginal implant group were vaginal or pelvic; 7.4% (7 of 95) of recurrences in the pelvic radiation therapy (RT) group were vaginal and 16.8% were pelvic; 18.2% (8 of 44) of recurrences in the no adjuvant radiation group were vaginal and 31.8% pelvic. Because of the high degree of selection bias no valid comparisons can be made of recurrence-free interval in these groups. The 5-year recurrence-free interval for patients with negative surgical-pathological risk factors (other than grade and myoinvasion) was 92.7%; involvement of the isthmus/cervix 69.8%; positive pelvic cytology 56.0%; vascular space invasion 55.0%; pelvic node or adnexal metastases 57.8%; and aortic node metastases or gross laparotomy findings 41.2%. It is not clear that cervix invasion per se diminishes survival, because it is more often associated with poor tumor differentiation (34.7% versus 24.0%, grade 3) and deep myoinvasion (47.0 vs 18.6%) than cases without cervix invasion. The relapse rate among cervix-positive and -negative cases with grade 3 lesions and deep myoinvasion is not dramatically different (48.8% vs 39.8%). The proportion of failures which were vaginal/pelvic (34.6% for the surgery only group compared to 12.5% of the RT group) appears to favor the use of adjuvant radiation for patients with more than one-third myoinvasion and grade 2 or 3 tumor. There were 97 patients in the study group with malignant cytology of which 29.1% had regional/distant failure, which compares to 10.5% of the cytology-negative patients.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Murphy KT, et al. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. doi: 10.1016/s0360-3016(02)04404-8. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654437 Review. - Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study.
Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback NB, Kurman R, Thigpen JT. Morrow CP, et al. Gynecol Oncol. 1990 Feb;36(2):166-71. doi: 10.1016/0090-8258(90)90166-i. Gynecol Oncol. 1990. PMID: 2298404 Clinical Trial. - Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.
Touboul E, Belkacémi Y, Buffat L, Deniaud-Alexandre E, Lefranc JP, Lhuillier P, Uzan S, Jannet D, Uzan M, Antoine M, Huart J, Ganansia V, Milliez J, Blondon J, Housset M, Schlienger M. Touboul E, et al. Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):81-97. doi: 10.1016/s0360-3016(00)01571-6. Int J Radiat Oncol Biol Phys. 2001. PMID: 11316550 Clinical Trial. - An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.
Look KY, Brunetto VL, Clarke-Pearson DL, Averette HE, Major FJ, Alvarez RD, Homesley HD, Zaino RJ. Look KY, et al. Gynecol Oncol. 1996 Dec;63(3):304-11. doi: 10.1006/gyno.1996.0327. Gynecol Oncol. 1996. PMID: 8946863 Clinical Trial. - [Endometrial cancer: what's new?].
Narducci F, Lambaudie E, Sonoda Y, Papageorgiou T, Taïeb S, Cabaret V, Castelain B, Leblanc E, Querleu D. Narducci F, et al. Gynecol Obstet Fertil. 2003 Jul-Aug;31(7-8):581-96. doi: 10.1016/s1297-9589(03)00173-5. Gynecol Obstet Fertil. 2003. PMID: 14563602 Review. French.
Cited by
- Paraaortic lymph node metastasis in endometrial cancer patients: a comprehensive analysis of rates, survival outcomes, and risk factors through systematic review and meta-analysis.
Han L, Chen Y, Zheng A, Tan X, Chen H. Han L, et al. Front Oncol. 2024 Oct 31;14:1490347. doi: 10.3389/fonc.2024.1490347. eCollection 2024. Front Oncol. 2024. PMID: 39544303 Free PMC article. Review. - Effects of Weight Loss on Key Obesity-Related Biomarkers Linked to the Risk of Endometrial Cancer: A Systematic Review and Meta-Analysis.
Clontz AD, Gan E, Hursting SD, Bae-Jump VL. Clontz AD, et al. Cancers (Basel). 2024 Jun 11;16(12):2197. doi: 10.3390/cancers16122197. Cancers (Basel). 2024. PMID: 38927903 Free PMC article. Review. - Intensity-modulated vaginal brachytherapy applicator and single- and multi-channel applicators in vaginal cuff brachytherapy.
Biltekin F, Akyol HF, Gultekin M, Yilmaz MT, Yildiz F. Biltekin F, et al. J Contemp Brachytherapy. 2024 Apr;16(2):132-138. doi: 10.5114/jcb.2024.138979. Epub 2024 Apr 18. J Contemp Brachytherapy. 2024. PMID: 38808211 Free PMC article. - Efficacy of Single- and Dual-Docking Robotic Surgery of Paraaortic and Pelvic Lymphadenectomy in High-Risk Endometrial Cancer.
Bizoń M, Olszewski M, Grabowska A, Siudek J, Mawlichanów K, Pilka R. Bizoń M, et al. J Pers Med. 2024 Apr 23;14(5):441. doi: 10.3390/jpm14050441. J Pers Med. 2024. PMID: 38793024 Free PMC article. - High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.
Matoba Y, Devins KM, Milane L, Manning WB, Mazina V, Yeku OO, Rueda BR. Matoba Y, et al. Reprod Sci. 2024 Sep;31(9):2541-2559. doi: 10.1007/s43032-024-01544-5. Epub 2024 Apr 24. Reprod Sci. 2024. PMID: 38658487 Review.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical